** Drug developer Neumora Therapeutics' shares fall 82% to $1.95

** NMRA says its experimental depression drug, navacaprant, did not meet the main goal in a late-stage trial

** The drug did not reduce symptoms of depression as measured on a disease severity scale that tracks sadness, reduced sleep and pessimistic thoughts

** NMRA says the drug also did not show statistically significant improvement on a key secondary goal

** Co says its cash balance of $342 mln at the end of the Q3 will fund operations into mid-2026

** NMRA declined ~38% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))